设计和开发体外共培养装置,用于研究不同组织微环境中的细胞串扰。
Design and development of in-vitro co-culture device for studying cellular crosstalk in varied tissue microenvironment.
发表日期:2024 Jul 05
作者:
Pooja Makwana, Unnati Modi, Bindiya Dhimmar, Rajesh Vasita
来源:
Bone & Joint Journal
摘要:
尽管处于不同的微环境中,乳腺癌细胞仍然影响骨细胞并促使癌症从乳房转移到骨骼。人们已经探索了多种共培养方法来研究这些细胞之间的旁分泌信号传导并研究癌症的进展。然而,缺乏天然组织微环境仍然是现有共培养技术的主要瓶颈。因此,在本研究中,致瘤和成骨微环境已被缝合在一起以创建多细胞环境,并已被评估用于研究骨组织中的癌症进展。 PCL-聚苯乙烯和PCL-胶原纤维支架分别针对MDA-MB-231和MC3T3-E1细胞的致瘤和成骨潜力诱导进行了表征。利用结晶紫、葡萄糖和牛血清白蛋白跨膜的扩散能力来了解装置促进的潜在旁分泌相互作用。在共培养条件下,MDA-MB-231细胞表现出EMT表型,并分泌TNFα和PTHrP,从而降低成骨标志物的表达,包括碱性磷酸酶、RUNX2、骨钙素和骨保护素。骨微环境中的癌症进展证明了创建多个组织微环境的作用和必要性及其在研究多细胞疾病进展和治疗方面的贡献。版权所有 © 2024 Elsevier B.V. 保留所有权利。
Despite of being in different microenvironment, breast cancer cells influence the bone cells and persuade cancer metastasis from breast to bone. Multiple co-culture approaches have been explored to study paracrine signaling between these cells and to study the progression of cancer. However, lack of native tissue microenvironment remains a major bottleneck in existing co-culture technologies. Therefore, in the present study, a tumorigenic and an osteogenic microenvironment have been sutured together to create a multi-cellular environment and has been appraised to study cancer progression in bone tissue. The PCL-polystyrene and PCL-collagen fibrous scaffolds were characterized for tumorigenic and osteogenic potential induction on MDA-MB-231 and MC3T3-E1 cells respectively. Diffusion ability of crystal violet, glucose, and bovine serum albumin across the membrane were used to access the potential paracrine interaction facilitated by device. While in co-cultured condition, MDA-MB-231 cells showed EMT phenotype along with secretion of TNFα and PTHrP which lower down the expression of osteogenic markers including alkaline phosphatase, RUNX2, Osteocalcin and Osteoprotegerin. The cancer progression in bone microenvironment demonstrated the role and necessity of creating multiple tissue microenvironment and its contribution in studying multicellular disease progression and therapeutics.Copyright © 2024 Elsevier B.V. All rights reserved.